![Stanley G. Miele](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stanley G. Miele
Gründer bei Aqualung Therapeutics Corp.
Aktive Positionen von Stanley G. Miele
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Sucampo Pharma Americas LLC | Präsident | 01.09.2009 | - |
Aqualung Therapeutics Corp.
![]() Aqualung Therapeutics Corp. BiotechnologyHealth Technology Aqualung Therapeutics Corp. is an early-stage biotech company based in Tucson, AZ. The private company is focused on developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung and systemic inflammation. Aqualung Therapeutics is developing enamptor™, a next-gen platform comprised of a humanized enampt-neutralizing monoclonal antibody, a plasma-based biomarker panel, and a genotyping assay that identifies individuals at increased risk for ARDS death. The pipeline of alt is designed to target a range of diseases, including ARDS, ventilator- and radiation-induced lung injury, chorioamnionitis, prostate cancer, pulmonary hypertension, and both pulmonary and hepatic fibrosis (NASH), conditions each with significant unmet medical needs and with significant morbidity and mortality. Founded in 2016 by Stanley G. Miele and Joe G. N. Garcia, the company is led by Joe G. N. Garcia, who has been the CEO since incorporation. | Direktor/Vorstandsmitglied | 01.10.2018 | - |
Gründer | 01.10.2018 | - | |
Präsident | 01.10.2018 | - |
Karriereverlauf von Stanley G. Miele
Ehemalige bekannte Positionen von Stanley G. Miele
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Abbott Point of Care, Inc.
![]() Abbott Point of Care, Inc. Medical SpecialtiesHealth Technology Abbott Point of Care, Inc. manufactures handheld blood analysers. The company is headquartered in Princeton, NJ. | Vertrieb & Marketing | 01.02.2006 | 01.02.2006 |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Vertrieb & Marketing | 01.01.2003 | 01.09.2005 |
SUCAMPO PHARMACEUTICALS, INC. | Präsident | 15.09.2009 | 08.01.2013 |
Vertrieb & Marketing | 01.02.2006 | - |
Ausbildung von Stanley G. Miele
University of Dayton | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
President | 3 |
Sales & Marketing | 3 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
Sucampo Pharmaceuticals, Inc.
![]() Sucampo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. The company was founded by Ryuji Ueno and Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD. | Health Technology |
Abbott Point of Care, Inc.
![]() Abbott Point of Care, Inc. Medical SpecialtiesHealth Technology Abbott Point of Care, Inc. manufactures handheld blood analysers. The company is headquartered in Princeton, NJ. | Health Technology |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Sucampo Pharma Americas LLC | |
Aqualung Therapeutics Corp.
![]() Aqualung Therapeutics Corp. BiotechnologyHealth Technology Aqualung Therapeutics Corp. is an early-stage biotech company based in Tucson, AZ. The private company is focused on developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung and systemic inflammation. Aqualung Therapeutics is developing enamptor™, a next-gen platform comprised of a humanized enampt-neutralizing monoclonal antibody, a plasma-based biomarker panel, and a genotyping assay that identifies individuals at increased risk for ARDS death. The pipeline of alt is designed to target a range of diseases, including ARDS, ventilator- and radiation-induced lung injury, chorioamnionitis, prostate cancer, pulmonary hypertension, and both pulmonary and hepatic fibrosis (NASH), conditions each with significant unmet medical needs and with significant morbidity and mortality. Founded in 2016 by Stanley G. Miele and Joe G. N. Garcia, the company is led by Joe G. N. Garcia, who has been the CEO since incorporation. | Health Technology |
- Börse
- Insiders
- Stanley G. Miele
- Erfahrung